Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Understanding in Depth the Physical Inactivity of Patients With COPD: Comparison of the Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients
Up to this moment, the majority of studies assessing the level of physical activity in daily
life in patients with COPD are limited to a cross-sectional design, which does not take into
account natural variation of physical activity in daily life due to differences in climatic
conditions faced throughout the year. Preliminary evidences suggest that patients with COPD
have different physical activity levels according to the seasons of the year. However, the
limited current evidences do not allow us to know the magnitude of differences in the level
of daily physical activity in patients with COPD when taking into account climatic changes
resulting from different seasons of the year in cities and countries with contrasting
climatic conditions. This gap observed in the literature does not allow us at this moment to
know whether we should or not consider the season of the year as one of the main causes of
variability while assessing physical activity in daily life in patients with COPD.
The present project proposes to investigate the hypothesis that patients with COPD who live
in a place with less marked decrease in temperature between summer and winter (Londrina,
Brazil) have less variability in the level of physical activity in daily life through the
year in comparison to patients who live in a place with more marked climatic variability
during these seasons (Leuven, Belgium).
The sample will be composed by at least 20 patients with moderate-severe COPD from each
institution involved (Catholic University of Leuven, Belgium and State University of
Londrina, Brazil), adding up to 40 patients (see sample size calculation below). However,
the sample size could be increased if necessary to achieve intermediate calculation of the
sample power performed during the study. Both groups should be similar concerning
anthropometric characteristics, gender distribution and severity feature of the disease
(especially FEV1). Therefore, an eventual increase in the final number of patients may also
be necessary in case this similarity is not achieved in the final data collection of the
planned sample.
Data collection will be performed in the Laboratory of Research in Respiratory Physiotherapy
from the State University of Londrina (Londrina, Brazil) and in the University Hospital
Gasthuisberg from the Catholic University of Leuven (Leuven, Belgium).
The study has a longitudinal design. Two groups of patients, one group in Londrina and
another group in Leuven, will be simultaneously and objectively evaluated concerning their
physical activity in daily life during one week in two different moments: in January 2013
(winter in Leuven and summer in Londrina), and then the same two groups of patients will be
once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven
and winter in Londrina). Changes in the level of physical activity in daily life between
summer and winter in the two groups will then be compared. Monitoring of physical activity
in daily life: two activity monitors (the SenseWear armband and the Fitbit) will be
simultaneously worn during 7 consecutive days. The SenseWear armband (BodyMedia, Pittsburg,
PA, USA) is a multisensor composed by a biaxial accelerometer and physiologic sensors. It is
a small (8.8 x 5.6 x 2 cm) and lightweight (82g) monitor that is worn at the upper right arm
and was already validated for energy expenditure estimation in patients with COPD [12,13].
The Fitbit (Fitbit, Inc., San Francisco, CA, USA) is a recently released triaxial
accelerometer that is smaller (3.6 x 2.9 x 1 cm) and more lightweight (8g) than the
SenseWear. According to the manufacturer, the Fitbit can be used in different positions,
including at the waist. This device provides the number of steps, the distance walked and
the energy expenditure in calories, among other variables. In the 7 days of assessment, the
patient will remain with the device during 24 hours/day. The patients will be strictly
instructed to avoid changing their daily physical activity habits during the monitoring
period.
To characterize the sample, all patients will be submitted to spirometry, 6 minute walking
test (6MWT) and quality of life assessment (Chronic Respiratory Disease Questionnaire -
CRQ), also described in detail in the subsection "Methods".
For each patient, further information will be also registered: types of drugs used by the
patient, their dosage and how often these drugs are used in the last month before inclusion
in the study; characterization of the history of acute exacerbations occurred in the last
year (if it is the case); presence of respiratory insufficiency on admission or during the
study period (PaO2 < 60 mmHg and/or SpO2 < 90% with or without PaCo2 > 50 mmHg, breathing on
room air); need for long-term oxygen supplementation previously or during the study period;
practice or not of regular physical activity in the last year.
LOGISTICS INVOLVED IN DATA COLECTION IN BOTH CENTERS
In the first period of data collection (January 2013), the Brazilian coordinator of the
project (Prof. Fabio Pitta) will travel to Leuven to participate in data collection and
organization on site. The Brazilian project coordinator will arrive in Leuven two weeks
before the data collection, and in conjunction with the Belgian coordinator of the project
(Prof. Thierry Troosters) and the European researchers will prepare all necessary logistic
actions to ensure the adequate performance of the study. After the preparation period, data
collection itself will be performed in three weeks, with 15 patients being assessed in the
first week and 14 in the third week. Spirometry, 6MWT and CRQ will be performed on Friday,
and data collection of physical activity will be performed from Saturday to next week's
Saturday. The 1-week interval between the first and second weeks of assessment will be used
to download the data and discuss eventual issues raised in the first week of assessment, and
thus this justifies the need of 15 activity monitor devices (SenseWear and Fitbit) in each
center adding up to 60 necessary devices (as data collection will simultaneously occur in
both centers).
Previously, the Brazilian team involved in the project will be prepared by the Brazilian
coordinator with the same instruction, since the first period of data collection in Londrina
will occur simultaneously with Leuven. Therefore, the first period of data collection in
Londrina will be performed by the Brazilian researchers involved in the study, coordinated
from Leuven by Prof. Fabio Pitta. The research team will make sure that the Brazilian
researchers are prepared and trained to perform all assessments, including the objective
quantification of physical activity in daily life, as well as the identical application of
the 6MWT and CRQ in both centers.
In the second phase of data collection (July 2013), the European and the Brazilian
researchers will be responsible for the assessments with the same protocol trained and
performed in the first phase of data collection. Therefore, Prof. Fabio Pitta will
coordinate the data collection in Londrina while Prof. Thierry Troosters will coordinate the
data collection in Leuven to ensure the reproducibility of all the methods in the second
data collection moment..
After the second phase of data collection, further project activities will have the
coordination centralized in Londrina, with the Brazilian coordinator of the project.
STATISTICAL ANALYSIS AND SAMPLE SIZE CALCULATION
Statistical analysis will be performed using the SPSS v. 17 Statistical Package (SPSS, Inc.,
Chicago IL, EUA) and the GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, EUA).
The Shapiro-Wilk test will be initially used to analyze the normality in data distribution.
In case of variables normally distributed, data will be described as mean ± standard
deviation, and those variables with non-normal distribution will be described as median
[25%-75% interquartile range]. Summer-winter changes in the same group of patients will be
analyzed by the paired t test (parametric analysis) or the Wilcoxon test (non-parametric
analysis). Summer-winter differences between the two groups of patients (Londrina and
Leuven) will be analyzed by the unpaired t test (parametric analysis) or by the Mann-Whitney
(non-parametric analysis). Variables of spirometry, 6MWT and CRQ of both groups will be
analyzed by the unpaired t test in the two assessment moments. Correlations will be analyzed
by the Pearson or Spearman coefficient, depending on the normality on data distribution. For
all analysis, statistical significance will be set at p less than 0.05.
The sample size of the study was calculated according to the assumption of a mean (and
standard deviation) difference of counts/day between two groups of patients with COPD, being
one in Europe and one in Brazil. The first group was assessed in the summer and winter, as
found in the study by Sewell et al. performed in England [10]. This study presented a mean
difference of 5656 counts (8857 in summer and 3201 in winter), with a standard deviation of
7497 and 2629 counts, respectively. The second group was based on our hypothesis that there
will be no (or little) change in physical activity in daily life due to seasonal variation
in Londrina (Brasil) based on the study by Probst et al. (Respiratory Care 2011; 56[11]:
1799-87), taking into account a similar standard deviation of 5063 counts/day. With a power
of 90%, alfa coefficient of 0.05, at least 12 patients in each group will be necessary to
detect significant difference in the level of physical activity in daily life between summer
and winter within the groups. Taking into account an eventual difficult setting with
drop-out rate of 40% due to difficulties in the data collection protocol involving the
motion sensors, a minimum of 20 patients will be included to compose either group (Londrina
and Leuven), adding up to 40 patients in total.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|